Lobbying Filing Details

Total Spending

$1,140,000

Activities

6

Lobbyists

4

Gov't Entities

19

Filing Information
Filing UUID:
d4013a0c-114b-4834-958d-175ba7710491
Type:
Q2 - 2nd Quarter - Report
Period:
2025 - 2nd Quarter (Apr 1 - June 30)
Date Posted:
July 16, 2025 at 4:56 PM
Income:
$0
Expenses:
$1,140,000
Expense Method:
A
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Samantha Ventimiglia
Registrant
VERTEX PHARMACEUTICALS INCORPORATED

Global biotechnology company

Boston, Massachusetts
Client
VERTEX PHARMACEUTICALS INCORPORATED
Massachusetts, United States of America
Lobbying Activities (6)
Activity 1
Budget/Appropriations

Education about non-opioid pain therapies and patient access to non-opioid medicines; Education on alternative funding programs; Education on the Million Veteran Program at the VA.

Lobbyists (4)
  • MATTHEW O SCHUMAKER
  • SWARNA VALLURUPALLI
  • MS. HANNAH BETH CORNWELL
  • MS. KRISTIN "SEUM" RICHTER
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 2
Health Issues

Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.

Lobbyists (4)
  • MATTHEW O SCHUMAKER
  • SWARNA VALLURUPALLI
  • MS. HANNAH BETH CORNWELL
  • MS. KRISTIN "SEUM" RICHTER
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 3
Medicare/Medicaid

Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals; Issues regarding the One Big Beautiful Bill Act (PL 119-21).

Lobbyists (4)
  • MATTHEW O SCHUMAKER
  • SWARNA VALLURUPALLI
  • MS. HANNAH BETH CORNWELL
  • MS. KRISTIN "SEUM" RICHTER
Government Entities (7)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Congressional Budget Office (CBO)
  • White House Office
  • Office of Management & Budget (OMB)
  • ... and 2 more
Activity 4
Pharmacy

Issues related to the National Defense Authorization Act - access to non-opioids for service members and their families.

Lobbyists (3)
  • SWARNA VALLURUPALLI
  • MS. HANNAH BETH CORNWELL
  • MS. KRISTIN "SEUM" RICHTER
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 5
Taxation/Internal Revenue Code

Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit; Restoration of Sec 174 R&D Expense Deductibility; Issues related to the One Big Beautiful Bill Act (PL 119-21).

Lobbyists (1)
  • SWARNA VALLURUPALLI
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 6
Trade (domestic/foreign)

Intellectual property reforms to address unfair trade practices in Argentina and Russia.

Lobbyists (1)
  • MATTHEW O SCHUMAKER
Government Entities (4)
  • U.S. Trade Representative (USTR)
  • Commerce, Dept of (DOC)
  • State, Dept of (DOS)
  • Patent & Trademark Office (PTO)

Source: LDA.gov, data retrieved November 9, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.